Partial Nephrectomy Allowed By Anti CD20 Antibody Treatment for Renal Cancer Associated with Acquired Haemophilia A


The case of a forty-five year old woman is presented who consulted for spontaneous haematomas of the thighs. The diagnosis of acquired haemophilia A associated to renal cancer was retained. She received anti CD20 monoclonal antibody treatment allowing her to undergo partial nephrectomy 4 months later without major complication. One year after surgery there is no sign of tumour recurrence.

Share and Cite:

T. Kullmann, A. Ankri, M. Bitker, S. Herson and O. Benveniste, "Partial Nephrectomy Allowed By Anti CD20 Antibody Treatment for Renal Cancer Associated with Acquired Haemophilia A," Journal of Cancer Therapy, Vol. 2 No. 3, 2011, pp. 308-310. doi: 10.4236/jct.2011.23041.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] V. Toschi and F. Baudo, “Diagnosis, Laboratory Aspects and Management of Acquired Hemophilia A,” Internal and Emergency Medicine, Vol. 5, No. 4, 2010, pp. 325- 333. doi:10.1007/s11739-010-0380-y
[2] A. Huth-Kühne, F. Baudo, P. Collins, J. Ingerslev, C. M. Kessler, H. Lévesque, M. Castellano, M. Shima M and J. St-Louis, “International Recommendations on the Diagnosis and Treatment of Patients with Acquired Hemophilia A,” Haematologica, Vol. 94, No. 4, 2009, pp. 566-575.
[3] M. Franchini, D. Veneri, G. Lippi and R. Stenner, “The Efficacy of Rituximab in the Treatment of Inhibitor Associated Hemostatic Disorders,” Journal of Thrombosis and Haemostasis, Vol. 96, No. 2, 2006, pp. 119-125.
[4] M. Franchini, G. Gandini, T. Di Paolantonio and G. Mariani, “Acquired Haemophilia A: A Concise Review,” American Journal of Hematology, Vol. 80, No. 1, 2005, pp. 55-63. doi:10.3324/haematol.2009.017749
[5] M. Wermke, M. von Bonin, S. Gehrisch, G. Siegert, G. Ehninger and U. Platzbecker, “Successful Eradication of Acquired Factor-VIII-Inhibitor Using Single Low-Dose Rituximab,” Haematologica, Vol. 95, No. 3, 2010, pp. 521-522. doi:10.3324/haematol.2009.017749

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.